UBS Upgrades Straumann to 'Buy' After Five Years, Citing Attractive Valuation and Earnings Momentum

UBS has upgraded Swiss dental implant manufacturer Straumann (STMN.S) to 'Buy' from 'Neutral', marking a significant shift after five years of maintaining a more cautious rating on the stock. The bank also raised its 12-month price target on the company to CHF 115.00 from CHF 90.00, suggesting a potential upside of approximately 23% from its previous closing price.

A More Achievable Outlook

According to a note from UBS, the primary driver for the upgrade is the belief that consensus forecasts have now reset to more achievable levels after a long period of what the bank considered overly ambitious market expectations. "We no longer think consensus estimates are persistently too ambitious, viewing consensus as at least deliverable, if not beat achievable," wrote UBS analyst Graham Doyle.

UBS is now forecasting a stronger performance for Straumann than the market consensus. The bank projects 10.3% organic revenue growth and a 26.1% core EBIT margin for the second half of 2026, ahead of consensus estimates of 9.8% and 25.7%, respectively. For 2027, UBS models 80 basis points of margin expansion, driven by cost savings from a new manufacturing facility in Shanghai and operational leverage.

Ad

Valuation and Easing Concerns

Analysts at UBS highlighted that key investor concerns regarding China's procurement policies, U.S. demand, and working capital are beginning to subside. The bank anticipates that an upcoming round of China's Volume-Based Procurement (VBP) policy will result in only a modest price reduction of 10% to 15%, which it expects to be largely offset by increased sales volume and market share gains.

From a valuation perspective, UBS noted that Straumann is trading at a compelling level. The stock's price-to-earnings premium over the European Healthcare index is currently around 10%, which is substantially below its 10-year average premium of 40%. This suggests, according to the bank, that there is "scope for a material valuation re-rating" as the company's earnings momentum improves.